Literature DB >> 15264429

Circulating nucleic acids in plasma and serum: past, present and future.

Bret Taback1, Dave S B Hoon.   

Abstract

Circulating nucleic acids have been detected in plasma/serum from cancer patients with a variety of tumor types. Polymerase chain reaction techniques provide a ubiquitous and facile approach for the identification of these tumor-associated genetic alterations from a minimal amount of tissue and body fluids. Increased levels of free DNA and RNA during malignancy, as well as in various medical conditions and infectious states, offers potential clinical utility for disease screening, diagnosis, prognosis, assessing occult disease progression, identifying potential therapeutic targets and monitoring treatment response. Additionally, elevated fetal DNA and RNA circulate in maternal blood and may serve as a diagnostic aide for assessing chromosomal abnormalities, fetal sexing and monitoring complications associated with pregnancy. Issues persist regarding the characteristics, etiology and potential pathological consequences of circulating cell-free DNA and RNA. Regardless, disease surveillance using nucleic acid-based assays for the evaluation of plasma/serum and body fluids provides a non-invasive and highly practical method for assessing patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15264429

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  19 in total

1.  Clinical proteomics: present and future prospects.

Authors:  Nicole M Verrills
Journal:  Clin Biochem Rev       Date:  2006-05

2.  Prognostic value of free DNA quantification in serum and cerebrospinal fluid in glioma patients.

Authors:  Wei Shi; Chenglin Lv; Jing Qi; Wei Zhao; Xiujie Wu; Rongrong Jing; Xinhua Wu; Shaoqing Ju; Jian Chen
Journal:  J Mol Neurosci       Date:  2011-09-01       Impact factor: 3.444

3.  Bov-tA short interspersed nucleotide element sequences in circulating nucleic acids from sera of cattle with bovine spongiform encephalopathy (BSE) and sera of cattle exposed to BSE.

Authors:  Ekkehard Schütz; Howard B Urnovitz; Leonid Iakoubov; Walter Schulz-Schaeffer; Wilhelm Wemheuer; Bertram Brenig
Journal:  Clin Diagn Lab Immunol       Date:  2005-07

4.  Epigenetic variations in breast cancer progression to lymph node metastasis.

Authors:  Guillermo Urrutia; Sergio Laurito; Diego M Marzese; Francisco Gago; Javier Orozco; Olga Tello; Teresita Branham; Emanuel M Campoy; María Roqué
Journal:  Clin Exp Metastasis       Date:  2015-01-28       Impact factor: 5.150

5.  Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients.

Authors:  Kazuo Koyanagi; Takuji Mori; Steven J O'Day; Steve R Martinez; He-Jing Wang; Dave S B Hoon
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

Review 6.  DNA methylation as a universal biomarker.

Authors:  Victor V Levenson
Journal:  Expert Rev Mol Diagn       Date:  2010-05       Impact factor: 5.225

7.  The MethDet: a technology for biomarker development.

Authors:  Victor V Levenson; Anatoliy A Melnikov
Journal:  Expert Rev Mol Diagn       Date:  2011-11       Impact factor: 5.225

8.  Circulating microRNAs in plasma of patients with gastric cancers.

Authors:  M Tsujiura; D Ichikawa; S Komatsu; A Shiozaki; H Takeshita; T Kosuga; H Konishi; R Morimura; K Deguchi; H Fujiwara; K Okamoto; E Otsuji
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

9.  Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer.

Authors:  Clemens Hufnagl; Michael Leisch; Lukas Weiss; Thomas Melchardt; Martin Moik; Daniela Asslaber; Geisberger Roland; Philipp Steininger; Thomas Meissnitzer; Daniel Neureiter; Richard Greil; Alexander Egle
Journal:  Oncol Lett       Date:  2019-12-09       Impact factor: 2.967

10.  Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.

Authors:  K Beiske; S A Burchill; I Y Cheung; E Hiyama; R C Seeger; S L Cohn; A D J Pearson; K K Matthay
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.